… Pharma, which markets patented drugs including Ilumya, a psoriasis treatment approved by the US FDA … drugs are copies of branded medications … drug exports Patented or branded drugs … are original formulations under patent protection, often developed …

… of developing dry eye disease were significantly higher in those with psoriasis … occlusion—require prompt diagnosis and treatment to prevent vision-threatening outcomes … threshold for referring patients with psoriasis for ophthalmic evaluation, particularly …

… titled “global benchmark for efficient drug pricing (GLOBE) model” … drugs.” Drugmakers have rolled out programs offering some of their meds … to offer its plaque psoriasis oral med Sotyktu at … pharma said it plans to charge its novel schizophrenia treatment, …

… clinic to get treatment for psoriasis, taking an average … stem cells that are developing into skin cells, … psoriasis. In lab dishes, ultrafine particles can also disrupt the normal development … pollution, governments should develop stronger early warning systems …

… increased prices for medications, quoting Oxford Economics … , which treats schizophrenia, and Sotyktu, which treats psoriasis. It … areas." Other pharmaceutical companies that have … developed Leqembi, an Alzheimer's drug, with Biogen. It received FDA …

… begin selling its psoriasis drug Sotyktu online at … drug appeared to slow neurodegeneration faster than the marketed treatment … pulmonary arterial hypertension drug developer Respira Therapeutics, the … buyout of Zynerba Pharmaceuticals. The compound previously …

… — Ipca Laboratories Ltd. and Torrent Pharma — were higher by as much … generic drugs that may not be affected by tariffs. Sun Pharmaceutical Industries … patented drugs, including Ilumya, a psoriasis treatment approved by the US Food & Drug Association …

… type 2 diabetes. By simplifying treatment and improving adherence, the therapy … for moderate-to-severe plaque psoriasis. The initiative aims to make … of a broader trend of pharma companies developing patient-centric access models …

… with delivery of the drugs to any state in … has raised concerns about pharma';s influencing prescriber behaviour … by the FDA as a first-in-class treatment for plaque psoriasis in … also filed the drug for FDA approval as a treatment for psoriatic arthritis …

… the treatment of moderate-to-severe plaque psoriasis: Results … milligrams. They took the medication once-daily. The … significance to clinicians treating patients with psoriasis using icotrokinra. “I … “We really need a drug that provides superior efficacy, …